Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GLUE Monte Rosa Therapeutics	$4.40 -3.5%	$4.96	$3.50 ▼ $12.40	$271.74M	1.42	604,141 shs	376,697 shs
GPCR Structure Therapeutics	$18.80 -5.8%	$19.42	$13.22 ▼ $45.37	$1.08B	-1.89	877,402 shs	1.03 million shs
RCUS Arcus Biosciences	$10.04 -4.1%	$9.18	$6.50 ▼ $18.98	$1.11B	0.89	1.03 million shs	872,087 shs
SYRE Spyre Therapeutics	$16.11 -4.9%	$16.26	$10.91 ▼ $40.26	$973.04M	2.82	611,934 shs	530,058 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GLUE Monte Rosa Therapeutics	-0.44%	+8.83%	-23.23%	+9.62%	-2.56%
GPCR Structure Therapeutics	-0.80%	+13.99%	+3.69%	-19.09%	-46.23%
RCUS Arcus Biosciences	+0.58%	+13.77%	+14.21%	+17.95%	-33.01%
SYRE Spyre Therapeutics	-0.06%	+11.08%	+3.99%	+10.00%	-34.95%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GLUE Monte Rosa Therapeutics	2.8214 of 5 stars	3.3	1.0	2.7	1.7	1.9
GPCR Structure Therapeutics	2.306 of 5 stars	3.5	3.0	0.9	1.7	0.6
RCUS Arcus Biosciences	2.2247 of 5 stars	3.4	3.0	2.2	1.7	0.0
SYRE Spyre Therapeutics	2.8917 of 5 stars	3.6	2.0	3.5	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GLUE Monte Rosa Therapeutics	2.67	Moderate Buy	$15.33	248.48% Upside
GPCR Structure Therapeutics	3.00	Buy	$75.71	302.74% Upside
RCUS Arcus Biosciences	2.75	Moderate Buy	$21.14	110.59% Upside
SYRE Spyre Therapeutics	3.29	Buy	$53.40	231.47% Upside

Current Analyst Ratings Breakdown

Latest GLUE, GPCR, RCUS, and SYRE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$75.00 ➝ $60.00
8/7/2025	GPCR Structure Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$92.00 ➝ $90.00
8/7/2025	GPCR Structure Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$89.00 ➝ $87.00
8/7/2025	RCUS Arcus Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$26.00 ➝ $25.00
8/6/2025	SYRE Spyre Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$65.00
6/23/2025	GPCR Structure Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$65.00
6/23/2025	GPCR Structure Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$89.00

(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GLUE Monte Rosa Therapeutics	$75.62M	3.59	N/A	N/A	$3.63 per share	1.21
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$15.10 per share	N/A
RCUS Arcus Biosciences	$262M	4.08	N/A	N/A	$5.30 per share	1.89
SYRE Spyre Therapeutics	$890K	1,093.31	N/A	N/A	$7.04 per share	2.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GLUE Monte Rosa Therapeutics	-$72.70M	$0.36	12.22	N/A	N/A	13.58%	9.95%	6.42%	11/6/2025 (Estimated)
GPCR Structure Therapeutics	-$122.53M	-$1.05	N/A	N/A	N/A	N/A	-21.31%	-20.34%	N/A
RCUS Arcus Biosciences	-$283M	-$3.17	N/A	N/A	N/A	-109.56%	-55.96%	-25.73%	11/5/2025 (Estimated)
SYRE Spyre Therapeutics	-$208.02M	-$3.40	N/A	N/A	N/A	N/A	-71.30%	-38.69%	11/6/2025 (Estimated)

Latest GLUE, GPCR, RCUS, and SYRE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	GLUE Monte Rosa Therapeutics	-$0.31	-$0.15	+$0.16	-$0.15	$7.23 million	$23.19 million
8/6/2025	Q2 2025	GPCR Structure Therapeutics	-$0.28	-$0.36	-$0.08	-$0.36	N/A	N/A
8/6/2025	Q2 2025	RCUS Arcus Biosciences	-$1.14	-$1.1053	+$0.0347	N/A	$32.86 million	$160.00 million
8/5/2025	Q2 2025	SYRE Spyre Therapeutics	-$0.73	-$0.49	+$0.24	-$0.49	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GLUE Monte Rosa Therapeutics	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GLUE Monte Rosa Therapeutics	N/A	7.16	7.16
GPCR Structure Therapeutics	N/A	20.48	20.48
RCUS Arcus Biosciences	0.18	4.50	4.50
SYRE Spyre Therapeutics	N/A	6.49	6.49

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GLUE Monte Rosa Therapeutics	79.96%
GPCR Structure Therapeutics	91.78%
RCUS Arcus Biosciences	92.89%
SYRE Spyre Therapeutics	80.39%

Insider Ownership

Company	Insider Ownership
GLUE Monte Rosa Therapeutics	6.50%
GPCR Structure Therapeutics	5.60%
RCUS Arcus Biosciences	9.60%
SYRE Spyre Therapeutics	6.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GLUE Monte Rosa Therapeutics	90	61.76 million	57.75 million	Optionable
GPCR Structure Therapeutics	136	57.60 million	54.37 million	Optionable
RCUS Arcus Biosciences	500	106.43 million	96.21 million	Optionable
SYRE Spyre Therapeutics	73	60.40 million	56.66 million	Optionable

GLUE, GPCR, RCUS, and SYRE Headlines

Recent News About These Companies

Spyre Therapeutics (NASDAQ:SYRE) Trading Up 8.5% - Here's Why

August 15, 2025 | marketbeat.com

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Recommendation of "Buy" from Brokerages

August 12, 2025 | marketbeat.com

XTX Topco Ltd Makes New Investment in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

August 9, 2025 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Receives "Outperform" Rating from Wedbush

August 7, 2025 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Releases Quarterly Earnings Results, Beats Estimates By $0.19 EPS

August 6, 2025 | marketbeat.com

Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 5, 2025 | globenewswire.com

TD Asset Management Inc Has $361,000 Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

August 5, 2025 | marketbeat.com

Jefferies Financial Group Inc. Acquires 31,900 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)

August 2, 2025 | marketbeat.com

Spyre Therapeutics Announces Grants of Inducement Awards

August 1, 2025 | globenewswire.com

Spyre Therapeutics (SYRE) Projected to Post Quarterly Earnings on Wednesday

July 31, 2025 | marketbeat.com

Victory Capital Management Inc. Sells 16,230 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)

July 28, 2025 | marketbeat.com

Here's Why We're Not Too Worried About Spyre Therapeutics' (NASDAQ:SYRE) Cash Burn Situation

July 16, 2025 | finance.yahoo.com

SYRE - Spyre Therapeutics Inc Trailing Returns - Morningstar

July 4, 2025 | morningstar.comM

Spyre Therapeutics Announces Grants of Inducement Awards

July 3, 2025 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE) and UnitedHealth (UNH)

June 20, 2025 | theglobeandmail.com

Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward

June 18, 2025 | seekingalpha.com

Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development ...

June 17, 2025 | finanznachrichten.de

Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts

June 17, 2025 | prnewswire.com

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025

June 16, 2025 | prnewswire.com

Spyre Therapeutics Announces Grants of Inducement Awards

June 6, 2025 | prnewswire.com

Wall Street Analysts Predict a 244.05% Upside in Spyre Therapeutics (SYRE): Here's What You Should Know

May 30, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLUE, GPCR, RCUS, and SYRE Company Descriptions

Monte Rosa Therapeutics NASDAQ:GLUE

$4.40 -0.16 (-3.51%)

Closing price 04:00 PM Eastern

Extended Trading

$4.39 -0.01 (-0.11%)

As of 05:50 PM Eastern

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Structure Therapeutics NASDAQ:GPCR

$18.80 -1.16 (-5.81%)

Closing price 04:00 PM Eastern

Extended Trading

$19.18 +0.38 (+1.99%)

As of 06:41 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Arcus Biosciences NYSE:RCUS

$10.04 -0.43 (-4.11%)

Closing price 03:59 PM Eastern

Extended Trading

$10.07 +0.03 (+0.30%)

As of 04:33 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Spyre Therapeutics NASDAQ:SYRE

$16.11 -0.83 (-4.90%)

Closing price 04:00 PM Eastern

Extended Trading

$15.84 -0.27 (-1.68%)

As of 04:25 PM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time